PB1820 PREBEN, PIXANTRONE, RITUXIMAB, ETOPOSIDE AND BENDAMUSTINE, IN AGGRESSIVE NON‐HOGDKIN LYMPHOMA

• Published in: HemaSphere 2019-06, Vol.3 (S1), p.833-834
• Main Authors: Barrenetxea, C., Alaez, C., Herraez, S., Romero, S., Hernández, L., Alonso, C., Blanco, Á., Navarro, B., Capote, F.J., Caballero, D., Leal, I., Uriarte, J., Diez, Z., Marquez, J.A.
• Format: Article
• Language: English
• ISSN: 2572-9241; 2572-9241
• DOI: 10.1097/01.HS9.0000565784.31046.7c

Background: Diffuse large B‐cell Lymphoma (DLBCL) is the most common subtype of Non‐Hodgkin‘s Lymphoma. It represents 30% of lymphomas in elderly age, with a 5‐year survival of 26‐73% depending on the risk factors. The WHO considers follicular lymphoma grade 3 A, as high grade lymphoma, and grade 3B as Diffuse Large B Cell Lymphoma (DLBCL), so that they are usually treated with the same protocols than DLBCL. First‐line therapies achieve complete response (CR) in 44‐87% of cases. Relapsed or refractory (R/R) DLBCL patients to first‐line treatment, usually receive salvage chemotherapy followed by autologous hematopoietic stem cell transplantation (SCT) as consolidative therapy. This second‐line therapy is not standardized and normally consists of polychemotherapy combinations. In patients who need third‐line therapy, survival results are even worse and nowadays there‘s not a protocolized treatment. Aims: Pixantrone offers an alternative for R/R DLBCL patients with efficacy and a favorable safety profile based on a phase 3 clinical trial, which permitted its approval by the European Medicines Evaluation Agency (EMEA). In this study, pixantrone was given as a single‐agent salvage therapy in pretreated patients that did not respond to at least two previous chemotherapy regimens, either relapsed or refractory. Patients achieved good responses with low toxicity. Thirty percent of patients achieved objetive responses and 20% CR and not confirmed CRs. There have been some polychemotherapy combinations with Pixantrone previously described, which obtained better global and CR rates. Methods: We analyzed R/R aggressive non‐Hodgkin lymphopma patients treated with PREBEN scheme in Spain. Treatment regimen was administered as described in d’Amore et al in 13‐ICML, 2015: Pixantrone 50 mg/m2 iv day 1 and 8, Rituximab iv or sc day 1, Etoposide 100 mg/m2 iv day 1 and Bendamustine 90 mg/m2 iv day 1, given in 3‐week cycles, with a maximum number of 6 cycles. We included in the analysis only those patients that had received at least 2 complete cycles. Results: 15 patients were included in the analysis, 12 DLBCL, 2 transformed follicular lymphoma and one follicular grade 3A. 10 were refractary to prior therapy. Median age was 73 years (range, 45‐87). Mean number of previous polychemotherapy lines was 3. Autologous SCT addicional had been performed in 6 of them.Early responses were observed: 10 out of 15 (67%) patients achieved objective responses after cycle 2. Eight patients ac